Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Elihu H. Estey(University of Washington), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Holly Gundacker(Seattle Cancer Care Alliance), Stefan Faderl(Jazz Pharmaceuticals (United States)), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Zhuoxin Sun(Dana-Farber Cancer Institute), Martin S. Tallman(Memorial Sloan Kettering Cancer Center)
Journal of Clinical Oncology
February 17, 2010
10.1200/jco.2009.25.1066
Cited by 207

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k